Canadian Drug Company Passes Along “Splendid” News

Canadian Drug Company Passes Along “Splendid” News

By: Dylan Sikes – News

Thursday, May 21, 2020

Better to light a candle than to curse the darkness, the old saying goes, and Vancouver-headquartered Naturally Splendid Enterprises Ltd. (TSX-Venture:NSP) came out Thursday with an update regarding preparation for a phase 2 clinical trial treatment for COVID 19.

The company said Health Canada has performed an initial review of data for a Clinical Trial Application (CTA) and appears to have given the go-ahead for tests to proceed to which the completed CTA can continue its processing. This significant designation creates a clear path for the CTA to proceed.

CavaltinibTM, the drug to be evaluated in the clinical trial and licensed to the joint venture owned by Naturally Splendid, displays novel pharmacology and shown today to be a potential fit as a drug candidate for COVID-19 patient treatment.

Shares in NSP showed “splendid” growth, gaining 2.5 cents, or 62.5% late Thursday morning to 6.5 cents, on volume topping 5.8 million shares.

Copyright © 2020 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Here Comes the Sun: Junior Miner Reveals B.C. Field Program
Reliance Puts Out the Word
GTX Heralds Sales Figures of Flagship Product
Most Popular
FREE Newsletter

Back to Top